<DOC>
	<DOC>NCT02480751</DOC>
	<brief_summary>The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).</brief_summary>
	<brief_title>TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Nephrosclerosis</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<criteria>The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease The patient with progressive CRF The patient with secondary glomerular disease The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Chronic Renal Failure</keyword>
	<keyword>Prostaglandin</keyword>
	<keyword>Prostacyclin</keyword>
	<keyword>Glomerular Disease; Nephrosclerosis</keyword>
</DOC>